Evaluation of the Effects of Melatonin Supplementation on Coagulation in Patients with Haemorrhagic Stroke; A Randomized, Double-Blind, Controlled Trial
Introduction: Considering that hemorrhagic stroke patients are at higher risk for bleeding, administration of higher doses of melatonin with a controversial coagulation profile is a serious concern. Objective: This study aimed to investigate the possible effects of high doses of melatonin on bleeding parameters and blood hemostasis in hemorrhagic stroke patients. Methods: This study is a randomized, double-blind, prospective, controlled trial. Confirmed hemorrhagic stroke patients were divided into two groups. Participants were randomly assigned into the melatonin group (30 mg daily via gastric tube gavage for 5 consecutive days) or the control group. Each patient was monitored for 5 days, and 2 blood samples were taken and the effect of the intervention on coagulation factors and blood hemostasis were investigated. Result: In total, 30 patients were randomly assigned to melatonin (n=15) or control groups (n=15). there was no significant difference between the two groups in demographic and clinical characteristics. There was a significant decline in prothrombin time (PT) and fibrinogen levels in the melatonin group (p=0.011 & p<0.001, respectively). P-values for VII and VWB factors showed a significant increment in these two factors in the melatonin group after the intervention (p=0.035 & p=0.002, respectively). No significant changes in serum levels of D-dimer factor, APACHE II, and GCS scores were evident in the two groups after the intervention (p>0.05). Conclusion: Considering the favorable changes in coagulation parameters observed in this study, it could be concluded that melatonin can have both procoagulant and antithrombin properties.
2. Duan X, Wen Z, Shen H, Shen M, Chen G. Intracerebral hemorrhage, oxidative stress, and antioxidant therapy. Oxid Med Cell Longev. 2016; 2016: 1203285.
3. Wu HJ, Wu C, Niu HJ, Wang K, Mo LJ, Shao AW, et al. Neuroprotective mechanisms of melatonin in hemorrhagic stroke. Cell Mol Neurobiol. 2017;37(7):1173-85.
4. Amaral FGd, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch Endocrinol Metab. 2018;62(4):472-9.
5. Cipolla-Neto J, Amaral FGd. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev. 2018;39(6):990-1028.
6. Wirtz PH, Spillmann M, Bärtschi C, Ehlert U, Von Känel R. Oral melatonin reduces blood coagulation activity: a placebo‐controlled study in healthy young men. J Pineal Res. 2008;44(2):127-33.
7. Wirtz PH, Bärtschi C, Spillmann M, Ehlert U, Von Känel R. Effect of oral melatonin on the procoagulant response to acute psychosocial stress in healthy men: a randomized placebo‐controlled study. J Pineal Res. 2008;44(4):358-65.
8. Kornblihtt LI, Finocchiaro L, Molinas FC. Inhibitory effect of melatonin on platelet activation induced by collagen and arachidonic acid. J Pineal Res. 1993;14(4):184-91.
9. Lissoni P, Mandala M, Rossini F, Fumagalli L, Barni S. Thrombopoietic property of the pineal hormone melatonin. Hematology. 1999;4(4):335-43.
10. Pogan L, Bissonnette P, Parent L, Sauvé R. The effects of melatonin on Ca2+ homeostasis in endothelial cells. J Pineal Res. 2002;33(1):37-47.
11. Dianatkhah M, Najafi A, Sharifzadeh M, Ahmadi A, Sharifnia H, Mojtahedzadeh M, et al. Melatonin supplementation may improve the outcome of patients with hemorrhagic stroke in the intensive care unit. J Res Pharm Pract. 2017;6(3):173-7.
12. Saroukhani S, Emami‐Parsa M, Modabbernia A, Ashrafi M, Farokhnia M, Hajiaghaee R, et al. Aspirin for treatment of lithium‐associated sexual dysfunction in men: randomized double‐blind placebo‐controlled study. Bipolar Disord. 2013;15(6):650-6.
13. Romero A, Ramos E, Patiño P, Oset-Gasque MJ, López-Muñoz F, Marco-Contelles J, et al. Melatonin and nitrones as potential therapeutic agents for stroke. Front Aging Neurosci. 2016;8:281.
14. Yawno T, Mahen M, Li J, Fahey MC, Jenkin G, Miller SL. The beneficial effects of melatonin administration following hypoxia-ischemia in preterm fetal sheep. Fronti Cell Neurosci. 2017;11:296.
15. Gitto E, Reiter RJ, Sabatino G, Buonocore G, Romeo C, Gitto P, et al. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J Pineal Res. 2005;39(3):287-93.
16. Pashalieva I, Stancheva E, Decheva L, Nyagolov Y, Negrev N. Experimental data about melatonin effects on platelet count and functional activity. Compt Rend Acad Bulg Sci. 2012;65(6):855-60.
17. Nakamura RK, Tompkins E, Bianco D. Therapeutic options for immune‐mediated thrombocytopenia. J Vet Emerg Crit Care. 2012;22(1):59-72.
18. Girish KS, Paul M, Thushara RM, Hemshekhar M, Sundaram MS, Rangappa KS, et al. Melatonin elevates apoptosis in human platelets via ROS mediated mitochondrial damage. Biochem Biophys Res Commun. 2013;438(1):198-204.
19. Pashalieva I, Decheva L, Stancheva E, Nyagolov Y, Negrev N. Melatonin and luzindole–induced effects on integral blood coagulation parameters in rats. Compt Rend Acad Bulg Sci. 2014;67:1269-74.
20. Bekyarova G, Tancheva S, Hristova M. The effects of melatonin on burn-induced inflammatory responses and coagulation disorders in rats. Methods Find Exp Clin Pharmacol. 2010;32(5):299.
21. Tunali T, Sener G, Yarat A, Emekli N. Melatonin reduces oxidative damage to skin and normalizes blood coagulation in a rat model of thermal injury. Life Sci. 2005;76(11):1259-65.
22. Nyagolov Y, Stancheva E, Decheva L, Pashalieva I, Negrev N. Melatonin and luzindole effects on the activity of plasma clotting factors V, XI, XII and XIII in rat. Compt Rend Acad Bulg Sci. 2012;65(8):1151-6.
23. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382(20):e60.
24. Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, et al. COVID-19 presenting as stroke. Brain Behav Immun. 2020;87:115-9.
25. Negrev N, Nyagolov Y, Zarkova A, Pashalieva II, Stancheva E, Radkova D. Effects of Melatonin and Luzindole on plasma levels of tissue factor, tissue factor Pathway inhibitor and Von Willebrand factor in rats. Scripta Scientifica Medica. 2015;47(1):64-9.
26. Stancheva E, Zarkova A, Pashalieva I, Nyagolov Y, Negrev N. Melatonin inhibits the protein c anticoagulant Pathway in rats. Scripta Scientifica Medica. 2015;47(1):57-63.
|Issue||Vol 5 No 3 (2021): Summer (July)|
|Blood Coagulation Disorders Factor VII Fibrinogen Hemorrhagic Stroke Melatonin von Willebrand Factor|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|